RAMM Pharma Corp. Explores Strategic Sale Options
RAMM Pharma Corp. (CSE: RAMM), along with its wholly owned subsidiaries, is considering the sale of its subsidiary, Canapar Corp., and its industrial facility situated in Italy. This strategy aligns with the Company’s goal of enhancing operational efficiency and focusing on growth avenues in the cannabinoid industry.
Enhancing Shareholder Value
The exploration of a potential sale is part of RAMM's ongoing commitment to create value for shareholders. As the Company aims to streamline operations, it remains dedicated to enhancing its core businesses while seeking strategic opportunities that can bolster its long-term sustainability and success.
Ongoing Updates and Future Prospects
RAMM Pharma intends to keep its stakeholders informed regarding developments related to Canapar Corp. and the associated industrial facility. While discussions and evaluations are ongoing, there are no guarantees that a sale will be finalized. The Company underlines its focus on transparency during this strategic decision-making process.
About RAMM Pharma Corp.
RAMM Pharma has established itself as a key player in cannabinoids, focusing on the formulation of cannabis-based pharmaceuticals and other hemp-derived products. Operating in Uruguay, the Company has successfully registered several cannabinoid pharmaceutical products approved for sales in various Latin American countries. Moreover, RAMM's innovative pipeline includes numerous products, covering both nutritional hemp-based offerings and specialized veterinary solutions, in different stages of regulatory approval.
International Operations
The Company's European operations are well-integrated with facilities in Italy and Poland. The facilities are designed for large-scale extraction and processing, particularly with Canapar Corp. nearing full operational capacity. This expansion supports RAMM's vision to develop a diversified, robust cannabinoid production framework.
Our Subsidiaries
Several subsidiaries contribute to RAMM's mission in the cannabis sector. They include Canapar Corp., HemPoland Sp. Z o.o., Medic Plast SA, Yurelan SA, Glediser SA, and RAMM Pharma Holdings Corp. Each subsidiary plays a distinct role, enhancing the Company’s ability to serve its consumers and stakeholders effectively.
Stay Updated with RAMM Pharma
For those looking to stay connected with RAMM Pharma Corp., further information is readily available on their official website. The Company provides regular updates on its operations, products, and strategic direction, ensuring stakeholders remain informed about developments in the rapidly evolving cannabis market.
Contact Information
For more inquiries, you can reach out to:
José Roldan
Interim CFO
+598 99 057 301
jroldan@rammpharma.com
Frequently Asked Questions
What is RAMM Pharma Corp. exploring regarding Canapar?
RAMM Pharma Corp. is exploring strategic options for the potential sale of Canapar Corp. and its industrial facility.
What does RAMM Pharma aim to achieve with the potential sale?
The Company aims to enhance shareholder value and long-term sustainability through streamlined operations.
Where are RAMM Pharma's operations located?
RAMM Pharma operates in Uruguay, Italy, and Poland, among other regions, focusing on cannabinoid formulation and production.
Which subsidiaries does RAMM Pharma own?
RAMM owns several subsidiaries, including Canapar Corp., HemPoland, and Medic Plast SA, each contributing to its diverse operations.
How can I get more information about RAMM Pharma?
Further information can be found on RAMM Pharma's website or by contacting their office directly.
